Gilead Sciences (GILD) Stock Forecast & Price Target
GILD Analyst Ratings
Strong Buy
17Buy5Hold0Sell
Based on 22 analysts giving stock ratings to Gilead Sciences in the past 3 months
GILD Stock 12 Month Forecast
Average Price Target
MXN 3,244.14â–²(0.28% Upside)Based on 22 Wall Street analysts offering 12 month price targets for Gilead Sciences in the last 3 months. The average price target is MXN 3,244.14 with a high forecast of MXN 3,776.44 and a low forecast of MXN 2,435.80. The average price target represents a 0.28% change from the last price of MXN 3,235.00.
Past 12 Months12 Month ForecastDec2025Sep2026
HighMXN 3.78K
AverageMXN 3.24K
LowMXN 2.44K
Highest Price TargetHighestMXN 3,776.44Average Price TargetMXN 3,244.14Lowest Price TargetLowestMXN 2,435.80
Detailed List of Analyst Forecasts​
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Mohit Bansal | Wells Fargo | MXN 3,115.56→MXN 3,587.61 | buy | 10.90%Upside | Assigned | 10/30/26 | ||
| Geoff Meacham | Citi | MXN 3,115.56→MXN 3,549.85 | buy | 9.73%Upside | Reiterated | 10/30/26 | ||
| Joseph Stringer | Needham | MXN 3,209.97→MXN 3,776.44 | buy | 16.74%Upside | Reiterated | 10/30/26 | ||
| Michael Yee | UBS | MXN 3,304.38→MXN 3,682.02 | buy | 13.82%Upside | Assigned | 10/30/26 | ||
| Louise Chen | Scotiabank | MXN 3,342.15→MXN 3,776.44 | buy | 16.74%Upside | Reiterated | 10/30/26 | ||
| Terence Flynn | Morgan Stanley | MXN 3,077.79→MXN 3,455.44 | buy | 6.81%Upside | Assigned | 10/30/26 | ||
| Evan Seigerman | BMO Capital | MXN 3,285.50→MXN 3,474.32 | buy | 7.40%Upside | Reiterated | 10/30/26 | ||
| Tyler Van Buren | TD Cowen | MXN 3,021.15→MXN 3,304.38 | buy | 2.14%Upside | Reiterated | 10/30/26 | ||
| Chris Schott | J.P. Morgan | MXN 3,209.97→MXN 3,587.61 | buy | 10.90%Upside | Assigned | 10/30/26 | ||
| Gregory Renza | Truist Financial | MXN 2,983.38→MXN 3,417.67 | buy | 5.65%Upside | Reiterated | 10/30/26 | ||
| Umer Raffat | Evercore ISI | ― | buy | ― | Reiterated | 10/30/26 | ||
| Brian Abrahams | RBC Capital | MXN 2,379.15→MXN 2,473.56 | hold | -23.54%Downside | Reiterated | 10/29/26 | ||
| Carter Gould | Cantor Fitzgerald | MXN 2,926.74→MXN 3,304.38 | buy | 2.14%Upside | Reiterated | 10/29/26 | ||
| Salveen Richter | Goldman Sachs | MXN 2,681.27→MXN 2,926.74 | hold | -9.53%Downside | Reiterated | 10/29/26 | ||
| Emily Field | Barclays | MXN 2,737.92 | hold | -15.37%Downside | Reiterated | 10/28/26 |
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Mohit Bansal | 10/30/26 | MXN 3,115.56→MXN 3,587.61 | buy | 10.90%Upside | Assigned | Wells Fargo | ||
| Geoff Meacham | 10/30/26 | MXN 3,115.56→MXN 3,549.85 | buy | 9.73%Upside | Reiterated | Citi | ||
| Joseph Stringer | 10/30/26 | MXN 3,209.97→MXN 3,776.44 | buy | 16.74%Upside | Reiterated | Needham | ||
| Michael Yee | 10/30/26 | MXN 3,304.38→MXN 3,682.02 | buy | 13.82%Upside | Assigned | UBS | ||
| Louise Chen | 10/30/26 | MXN 3,342.15→MXN 3,776.44 | buy | 16.74%Upside | Reiterated | Scotiabank | ||
| Terence Flynn | 10/30/26 | MXN 3,077.79→MXN 3,455.44 | buy | 6.81%Upside | Assigned | Morgan Stanley | ||
| Evan Seigerman | 10/30/26 | MXN 3,285.50→MXN 3,474.32 | buy | 7.40%Upside | Reiterated | BMO Capital | ||
| Tyler Van Buren | 10/30/26 | MXN 3,021.15→MXN 3,304.38 | buy | 2.14%Upside | Reiterated | TD Cowen | ||
| Chris Schott | 10/30/26 | MXN 3,209.97→MXN 3,587.61 | buy | 10.90%Upside | Assigned | J.P. Morgan | ||
| Gregory Renza | 10/30/26 | MXN 2,983.38→MXN 3,417.67 | buy | 5.65%Upside | Reiterated | Truist Financial | ||
| Umer Raffat | 10/30/26 | ― | buy | ― | Reiterated | Evercore ISI | ||
| Brian Abrahams | 10/29/26 | MXN 2,379.15→MXN 2,473.56 | hold | -23.54%Downside | Reiterated | RBC Capital | ||
| Carter Gould | 10/29/26 | MXN 2,926.74→MXN 3,304.38 | buy | 2.14%Upside | Reiterated | Cantor Fitzgerald | ||
| Salveen Richter | 10/29/26 | MXN 2,681.27→MXN 2,926.74 | hold | -9.53%Downside | Reiterated | Goldman Sachs | ||
| Emily Field | 10/28/26 | MXN 2,737.92 | hold | -15.37%Downside | Reiterated | Barclays |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Gilead Sciences
3 Months
Success Rate17/21 ratings generated profit
81%
Average Return
+8.08%
Copying Courtney Breen's trades and holding each position for 3 Months would result in 80.95% of your transactions generating a profit, with an average return of +8.08% per trade.
1 Year
Success Rate26/26 ratings generated profit
100%
Average Return
+31.70%
Copying Geoff Meacham's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +31.70% per trade.
2 Years
Success Rate26/26 ratings generated profit
100%
Average Return
+58.99%
Copying Chris Schott's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +58.99% per trade.
GILD Analyst Recommendation Trends
| Rating | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 |
|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 |
| Buy | 58 | 53 | 56 | 35 | 52 |
| Hold | 13 | 13 | 11 | 9 | 12 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 71 | 66 | 67 | 44 | 64 |
In the current month, GILD has received 52 Buy Ratings, 12 Hold Ratings, and 0 Sell Ratings. GILD average Analyst price target in the past 3 months is 3,244.14.
GILD Financial Forecast
HighMXN 43.77
ConsensusMXN 26.15
LowMXN 17.28
GILD Earnings Forecast
Next quarter’s earnings estimate for GILD is MXN 26.15 with a range of MXN 17.28 to MXN 43.77. The previous quarter’s EPS was MXN 47.91. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
HighMXN 160B
ConsensusMXN 156B
LowMXN 151B
GILD Sales Forecast
Next quarter’s sales forecast for GILD is MXN 155.61B with a range of MXN 150.93B to MXN 160.29B. The previous quarter’s sales results were MXN 156.01B. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
GILD Stock Forecast FAQ
What is MX:GILD’s average 12-month price target, according to analysts?
Based on analyst ratings, Gilead Sciences’s 12-month average price target is Mex$3,244.14.
What is MX:GILD’s upside potential, based on the analysts’ average price target?
Gilead Sciences has 0.28% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Gilead Sciences a Buy, Sell or Hold?
Gilead Sciences has a consensus rating of Strong Buy, which is based on 17 buy ratings, 5 hold ratings and 0 sell ratings.
What is Gilead Sciences’s share price target?
The average share price target for Gilead Sciences is Mex$3,244.14. This is based on 22 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is Mex$3,776.44, and the lowest forecast is Mex$2,435.80. The average share price target represents a 0.28% increase from the current price of Mex$3,235.
What do analysts say about Gilead Sciences?
Gilead Sciences’s analyst rating consensus is a Strong Buy. This is based on the ratings of 22 Wall Street analysts.
How can I buy shares of Gilead Sciences?
To buy shares of MX:GILD, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.